New: NCI-funded clinical trial search
Mednet Logo

How do you manage immune-related toxicity from checkpoint inhibitors that is refractory to initial steroid therapy?

What immunosuppressive agents are used and in what order? Does your approach differ depending on the organ involved, e.g. colitis vs. pneumonitis?
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Duke University Medical Center
Answered on

Consensus guidelines recommend the use of steroid therapy for immune related adverse events irAE, and fortunately most toxicities (with the exception of endocrinopathies) are reversible. No prospective data exists on the management of irAE, including steroid refractory irAE. In most cases, we use infliximab, with the exceptions discussed below. In our experience, most patients experience improvement after only one dose, though occasionally patients have required 2 or 3 doses. For steroid refractory hepatitis, infliximab is contraindicated because of its potential hepatotoxic effects. In these cases we have used mycophenolate mofitil with success. For steroid refractory neurologic irAE, we have had anecdotal success with IVIG (Choe JH, et al...

Join for free or sign in to see the full answer